Sanofi, AstraZeneca clinch first OK for RSV antibody — just as vaccines line up at regulators
The EU has officially stamped its seal of approval for nirsevimab, the antibody jointly developed by Sanofi and AstraZeneca to prevent RSV disease in infants …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.